Sign Out
Pharmacotherapeutic group: Antineoplastic agent. ATC code: L01XA03.
Pharmacology: Oxaliplatin a cell phase nonspecific antineoplastic drug belongs to a new class of platinum agent that contains a platinum atom complexed with oxalate and diaminocyclohexane (DACH).
Mechanism of Action: The exact mechanism of action of oxaliplatin is not known. The mechanism of action of oxaliplatin is probably similar to that of cisplatin. Oxaliplatin forms reactive platinum complexes that are believed to inhibit DNA synthesis by forming interstrand and intrastrand cross-linking of DNA molecules. Oxaliplatin is not cross resistant to Cisplatin or Carboplatin, probably due to the DACH group and resistance to DNA mismatch repair. Oxaliplatin is a radiation sensitizing agent.
Pharmacokinetics: After intravenous distribution, Oxaliplatin is mainly accumulated in erythrocytes and does not diffuse into the plasma. 85-88% of platinum is protein bound in the first 5 hours after administration. Oxaliplatin undergoes rapid nonenzymatic biotransformation to reactive platinum complexes. The active metabolites of oxaliplatin are DACH platinum species. Oxaliplatin is excreted by renal excretion. Approximately 50% of the administered dose is excreted in the urine within the first 3 days. Fecal excretion is approximately 0.5% per day and reaches 5% of the total dose by day 11. The terminal half-life of ultra-filterable platinum (Oxaliplatin and free Oxaliplatin metabolites) is 273±19 hrs. The platinum elimination from the erythrocytes takes about 48 days.
